PTC Therapeutics price to free cash flow PTCT
Market value divided by free cash flow over the last twelve months, since 2018.
- Today, Nov 2, 2026
- n/m
- a sliver of free cash flow
- Last meaningful
- 7.7×
- May 2026
- 8-year median
- 8.0×
- 8-year range
- 5.1× to 425×
- Peer median
- 48.8×
PTC Therapeutics' price to free cash flow is not a meaningful number today: a multiple this high rests on a sliver of free cash flow.
It was last meaningful in May 2026, at 7.7×.
On the days it had one over the last 8 years, its median was 8.0×, from 5.1× in May 2025 to 425× in Jan 2019.
Price to free cash flow over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 7.7× | 7.4× | 8.8× |
| 2025 | 8.9× | 5.1× | 9.8× |
| 2024 | n/m a value too high to mean anything | ||
| 2023 | n/m a value too high to mean anything | ||
| 2022 | n/m a value too high to mean anything | ||
| 2021 | n/m a value too high to mean anything | ||
| 2020 | n/m a value too high to mean anything | ||
| 2019 | 390× | 349× | 425× |
| 2018 | 379× | 358× | 421× |
Against its peers
Companies in Drug Manufacturers - General nearest PTC Therapeutics' size, closest first, today.
| Company | Price to free cash flow |
|---|---|
| PTCTPTC Therapeutics | n/m |
| INDVIndivior Pharmaceuticals | 138× |
| LGNDLigand Pharmaceuticals | 46.6× |
| AMRXAmneal Pharmaceuticals | 51.1× |
| ARQTArcutis Biotherapeutics | 100× |
| LQDALiquidia | 24.9× |
| KNSAKiniksa Pharmaceuticals International | 38.7× |
| OGNOrganon | 5.4× |
| ALKSAlkermes plc. | 34.0× |
| CORTCorcept Therapeutics | 81.3× |
| PTGXProtagonist Therapeutics | 69.1× |
| Peer median | 48.8× |
What the price to free cash flow tells you
Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.
Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.
More on PTC Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.